---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059461"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:09:29.384974+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Q3 net loss narrows; exa-cel PDUFA: Dec 8 (SCD) & Mar 30, 2024 (TDT)

## Summary
- PDUFA target action date for exa-cel in sickle cell disease: Dec 8, 2023; for beta thalassemia: March 30, 2024.
- Net loss narrowed to $112.2M in Q3 2023 from $174.5M in Q3 2022; cash $1.74B.
- R&D expenses decreased to $90.7M from $116.6M; G&A down to $18.3M from $27.0M.
- Initiated Phase 1 trial for CTX310 targeting ANGPTL3; CTX320 on track for clinic in H1 2024.
- Proposed election of Sandy Mahatme to Board at 2024 annual meeting.

## SEC filing metadata
- accession: 0000950170-23-059461
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/0000950170-23-059461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/crsp-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059461
- JSON: https://secwatch.observer/filing/0000950170-23-059461.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059461.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/0000950170-23-059461-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.